Abstract
Introduction
Ewing's sarcoma is the second most common malignant bone tumour of childhood and adolescence, accounting for about one-third of the primary bone tumours and 2% of all cancers in children and young adults. Most cases (~80%) appear before the age of 18 years, and most of the remaining 20% occur before the age of 30 years, although the disease can emerge at any age [1] [2] [3] 
. Together with the malignant peripheral primitive neuroectodermal tumours (pPNET) it comprises the Ewing's Sarcoma Family of Tumors (ESFT). Similar to several other sarcomas, ESFT display an aggressive behaviour with a tendency towards recurrence following resection and pronounced tendency towards early haematogenous metastasis. As a result, the prognosis of chemoresistant and disseminated sarcomas remains excessively poor despite multimodal therapeutic approaches: 50% survival at 5 years (25% if metastases are present at diagnosis) and less than 30%
survival at 10 years [1] [2] [3] [4] . Thus, better understanding of the disease is required for the development of novel therapeutic modalities [5] .
Heparanase is an endoglycosidase which cleaves heparan sulphate (HS) side chains at a limited number of sites, activity that is strongly implicated in cell dissemination associated with tumour metastasis, inflammation and angiogenesis [6] [7] [8] [9] . In recent years, heparanase up-regulation was documented in an increasing number of human carcinomas [7, 10] . In many cases, heparanase induction correlated with increased tumour metastasis, vascular density and shorter post-operative survival of cancer patients, thus providing a strong clinical support for the pro-metastatic and pro-angiogenic functions of the enzyme. These results led to the development of heparanase inhibitors as anti-cancer drugs [9, [11] [12] [13] , including compound SST0001 (N-acetylated glycol-split heparin) a non-anticoagulant chemically modified heparin [14] , shown to effectively inhibit B16 melanoma lung colonization [15] and myeloma tumour growth [16, 17] , exerting no detectable side effects [16, 17] . The same inhibitor was applied in this study and found to efficiently suppress TC71 Ewing's sarcoma tumour growth.
Utilizing an ELISA method capable of detection and quantification of heparanase in urine and plasma samples [18, 19] , we have recently reported that heparanase levels are significantly elevated in the plasma of paediatric cancer patients [20] . Notably, heparanase levels in the plasma of sarcoma patients, including Ewing's sarcoma, correlated with therapy effectiveness [20] [14] . [20] .
Materials and methods

Cell culture
Matrigel invasion assay
Heparanase immunostaining
Staining of formalin-fixed, paraffin-embedded, 5-m sections for heparanase was performed essentially as described [20, 22, 23] 
Results
Inhibition of Ewing's sarcoma cell invasion and tumour growth by an inhibitor of heparanase
Based on the increasing awareness that heparanase expression is associated with cell invasion and tumour progression [7, 10] Fig. 2E ). 
Fig. 2 Immunohistochemical staining of heparanase in Ewing's sarcoma specimens. Formalin-fixed, paraffin-embedded 5 m sections were subjected to immunostaining, applying anti-heparanase polyclonal antibody (Ab 733), as described under 'Materials and methods'. Shown are representative photomicrographs of heparanase-positive specimens categorized as weak (ϩ1, A, B) or strong (ϩ2, C, D) intensity. Nuclear localization of heparanase is shown in (E). Specimens that were similarly stained with pre-immune serum, or applying the above procedure but lacking the primary antibody, yielded no detectable staining (F). Original magnification: (A, C) 100ϫ; (B, D-F) 400ϫ.
Clinical data of the patients
Heparanase staining intensity correlated with patients' age at diagnosis (Table 3) [28] . In contrast with the relative uniformity of the extent criteria, staining intensity varied and was categorized as weak (ϩ1; Fig. 2A, B) or strong (ϩ2; Fig. 2C, D) intensity. The most important prognostic factor in ESFT is the presence of metastatic disease in presentation [29] . Only one patient in this study was diagnosed as such. Investigating the association of heparanase with tumour metastasis, the hallmark of heparanase function [8, 30] Table 3 ). This is significant because the disease tends to be more aggressive in older patients [2, 31] . Worse outcome is also observed in patients with larger tumours [2, 31] [11, [40] [41] [42] . Several compounds with anti-heparanase activity have been identified, and one, PI-88, is currently being evaluated in clinical trials [11, 12, 43, 44] . In this study, we applied a non-anticoagulant chemically modified heparin (N-acetylated and glycol-split heparin, termed SST0001), shown to specifically inhibit heparanase enzymatic activity [9, 14] and effectively suppress B16 melanoma lung colonization [15] and myeloma tumour growth, with no detectable side effects [17] . The inhibitory action of compound SST0001 is attributed to its tight binding to heparanase facilitated by the enhanced flexibility of heparin afforded by the glycol splitting, which opens the sugar ring [9, 16] (Fig. 1A) . Moreover, tumour xenograft growth was markedly suppressed in mice treated with SST0001 relative to untreated animals (Fig. 1B) . The dose and schedule of SST0001 treatment used in this study were chosen on the basis of previous preclinical studies, performed in murine tumour models and human myeloma xenografts [16, 17] [16, 17] . The almost complete inhibition (~90%) of tumour growth in mice treated with compound SST0001, directed against heparanase enzymatic activity, indicates that in the case of Ewing's sarcoma, unlike, for example, U87 human glioma [33, 34] , non-enzymatic activities of the heparanase protein [32] [33] [34] [35] [36] [37] [43, 44] and haematological malignancies [17] .
